M Milella

Summary

Affiliation: Regina Elena Cancer Institute
Country: Italy

Publications

  1. ncbi request reprint Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia
    Michele Milella
    Department of Blood and Marrow Transplantation, Section of Molecular Hematology and Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 99:3461-4. 2002
  2. ncbi request reprint Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma
    Michele Milella
    Divisions of Medical Oncology A and C, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
    Cancer 101:133-8. 2004
  3. pmc Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies
    Giampaolo Tortora
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Naples, Italy
    Drug Resist Updat 10:81-100. 2007
  4. pmc Biology of metastatic renal cell carcinoma
    Michele Milella
    Division of Medical Oncology A, Regina Elena National Cancer Institute, Rome Italy
    J Cancer 2:369-73. 2011
  5. pmc Maintenance therapy in NSCLC: why? To whom? Which agent?
    Silvia Novello
    Thoracic Oncology Unit, University of Turin, AOU, San Luigi Orbassano, Italy
    J Exp Clin Cancer Res 30:50. 2011
  6. pmc A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study
    Flavia Novelli
    Pathology Department, Regina Elena Cancer Institute, Rome, Italy
    Breast Cancer Res 10:R74. 2008
  7. ncbi request reprint Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells
    Michele Milella
    Division of Medical Oncology A, Laboratory of Experimental Preclinical Chemotherapy, Laboratory B, Division of Pathology, and Division of Clinical Pathology, Regina Elena National Cancer Institute, Rome, Italy
    Clin Cancer Res 10:7747-56. 2004
  8. ncbi request reprint MEK blockade converts AML differentiating response to retinoids into extensive apoptosis
    Michele Milella
    Division of Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy
    Blood 109:2121-9. 2007
  9. ncbi request reprint The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies
    Michele Milella
    Division of Medical Oncology A, Regina Elena Cancer Institute, Via Elio Chianesi, n 53, 00144, Rome, Italy
    Rev Clin Exp Hematol 7:160-90. 2003
  10. ncbi request reprint Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects
    M Milella
    Division of Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy
    Curr Pharm Des 11:2779-95. 2005

Detail Information

Publications58

  1. ncbi request reprint Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia
    Michele Milella
    Department of Blood and Marrow Transplantation, Section of Molecular Hematology and Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 99:3461-4. 2002
    ..These findings show that the Bcl-2 and MAPK pathways are relevant molecular targets in AML and that their concurrent inhibition could be developed into a new therapeutic strategy for this disease...
  2. ncbi request reprint Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma
    Michele Milella
    Divisions of Medical Oncology A and C, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
    Cancer 101:133-8. 2004
    ..Cyclooxygenase-2 (COX-2) is up-regulated frequently and may constitute a promising therapeutic target in patients with pancreatic ductal adenocarcinoma (PDAC)...
  3. pmc Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies
    Giampaolo Tortora
    Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Naples, Italy
    Drug Resist Updat 10:81-100. 2007
    ....
  4. pmc Biology of metastatic renal cell carcinoma
    Michele Milella
    Division of Medical Oncology A, Regina Elena National Cancer Institute, Rome Italy
    J Cancer 2:369-73. 2011
    ....
  5. pmc Maintenance therapy in NSCLC: why? To whom? Which agent?
    Silvia Novello
    Thoracic Oncology Unit, University of Turin, AOU, San Luigi Orbassano, Italy
    J Exp Clin Cancer Res 30:50. 2011
    ....
  6. pmc A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study
    Flavia Novelli
    Pathology Department, Regina Elena Cancer Institute, Rome, Italy
    Breast Cancer Res 10:R74. 2008
    ..In particular, there are no data concerning ER-beta distribution within the novel molecular breast cancer subtypes luminal A (LA) and luminal B (LB), HER2 (HS), and triple-negative (TN)...
  7. ncbi request reprint Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells
    Michele Milella
    Division of Medical Oncology A, Laboratory of Experimental Preclinical Chemotherapy, Laboratory B, Division of Pathology, and Division of Clinical Pathology, Regina Elena National Cancer Institute, Rome, Italy
    Clin Cancer Res 10:7747-56. 2004
    ..To investigate the possible existence of an antiapoptotic cross-talk between HER-2 and antiapoptotic Bcl-2 family members...
  8. ncbi request reprint MEK blockade converts AML differentiating response to retinoids into extensive apoptosis
    Michele Milella
    Division of Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy
    Blood 109:2121-9. 2007
    ..Taken together, these results indicate that combined retinoid treatment and MEK blockade exert powerful antileukemic effects and could be developed into a novel therapeutic strategy for both AML and APL...
  9. ncbi request reprint The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies
    Michele Milella
    Division of Medical Oncology A, Regina Elena Cancer Institute, Via Elio Chianesi, n 53, 00144, Rome, Italy
    Rev Clin Exp Hematol 7:160-90. 2003
    ....
  10. ncbi request reprint Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects
    M Milella
    Division of Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy
    Curr Pharm Des 11:2779-95. 2005
    ..Here we briefly discuss evidence suggesting that MAPK pathway inhibition could play a prominent role in the development of integrated therapeutic strategies aimed at synergistic anti-leukemic effects...
  11. doi request reprint Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
    Alessandra Fabi
    Division of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy
    Oncology 78:141-9. 2010
    ..We investigated the clinical impact of the expression of PTEN, p-Akt and PI3K in HER2-positive metastatic breast cancer (MBC) patients treated with trastuzumab-based therapies...
  12. pmc Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non-small-cell lung cancer: a phase II study
    A F Scinto
    Division of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy
    Br J Cancer 81:1031-6. 1999
    ..Median OS for the entire group was 12.5 months (range 2-57+). The ICE regimen is active in locally advanced NSCLC with acceptable toxicity and warrants further exploration as induction chemotherapy in larger series...
  13. pmc Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis
    E Bria
    Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
    Ann Oncol 22:2277-85. 2011
    ..Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are effective as first-line treatment of advanced non-small-cell lung cancer patients with EGFR mutations (EGFR-M+)...
  14. doi request reprint Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers
    Maria S Pino
    Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
    Oncology 76:254-61. 2009
    ..We therefore evaluated a fully oral regimen of capecitabine and celecoxib (CapCel) as second-line treatment in these patients...
  15. pmc Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells
    V Folgiero
    Department of Experimental Oncology, Regina National Elena Cancer Institute, Via delle Messi d Oro 156, Rome, Italy
    Cell Death Dis 3:e440. 2012
    ....
  16. ncbi request reprint Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation
    Alessandra Fabi
    Division of Medical Oncology A, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
    Cancer Chemother Pharmacol 62:717-25. 2008
    ....
  17. ncbi request reprint Weekly docetaxel in pretreated metastatic breast cancer patients: a phase I-II study
    Cecilia Nistico
    Department of Medical Oncology, Regina Elena National Cancer Institute, Roma, Italy
    Oncology 68:356-63. 2005
    ..We conducted a phase I-II study to determine the maximum tolerated dose (MTD), toxicity and activity of weekly docetaxel administration in pretreated metastatic breast cancer patients...
  18. pmc Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials
    G Ferretti
    Department of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy
    Br J Cancer 94:1789-96. 2006
    ..Investigators should assess heterogeneity of trial results before deriving summary estimates of treatment effect...
  19. ncbi request reprint Sequential chemotherapy in nonsmall-cell lung cancer: cisplatin and gemcitabine followed by docetaxel
    Anna Ceribelli
    Division of Medical Oncology A, Regina Elena Cancer Institute, Rome, Italy
    Cancer 109:727-31. 2007
    ....
  20. ncbi request reprint Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues
    Emilio Bria
    Regina Elena National Cancer Institute, Department of Medical Oncology, Via Elio Chianesi 53, 00144, Rome, Italy
    Expert Opin Biol Ther 8:1963-71. 2008
    ..This result has been achieved in all disease settings, by increasing overall survival in early stage and advanced disease and by increasing pathological complete responses in neoadjuvant disease...
  21. ncbi request reprint Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients
    Emilio Bria
    Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
    Cancer 106:2337-44. 2006
    ..A pooled analysis of Phase III trials was performed to assess the advantages that adjuvant taxane chemotherapy has over standard chemotherapy...
  22. ncbi request reprint Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials
    Emilio Bria
    Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
    Cancer 110:525-33. 2007
    ..Several attempts have been made at improving the efficacy of gemcitabine in advanced pancreatic cancer by combining it with other chemotherapeutic or molecularly targeted agents. However, randomized trials have produced conflicting results...
  23. pmc Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations
    Ludovica Ciuffreda
    Division of Medical Oncology A, Regina Elena National Cancer Institute, 00144 Rome, Italy
    Neoplasia 11:720-31. 2009
    ..Deeper understanding of the molecular mechanisms of action of MEK inhibitors will likely translate into more effective treatment strategies for patients experiencing malignant melanoma...
  24. ncbi request reprint Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer
    E Bria
    Medical Oncology, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
    Eur J Surg Oncol 34:593-8. 2008
    ..Aim of our study was to determine the prognostic role of survivin as an apoptosis-related biomarker in a series of resected NSCLC patients...
  25. ncbi request reprint Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules
    E Terzoli
    Department of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy
    J Exp Clin Cancer Res 23:207-13. 2004
    ..In conclusion the results of the study showed that dose intensity of vinorelbine could have an improvement in terms of time to progression in pretreated advanced breast cancer...
  26. ncbi request reprint Adjuvant chemotherapy for non-small cell lung cancer
    Emilio Bria
    Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
    J Thorac Oncol 2:S7-11. 2007
    ..In this respect, the customized therapy based on molecular/genetic patient and disease features constitutes a new avenue to pursue...
  27. pmc Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines
    Maria S Pino
    Division of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
    Clin Cancer Res 14:4943-50. 2008
    ..The aim of this study was to determine whether or not the expression of hMena isoforms correlated with sensitivity to EGFR tyrosine kinase inhibitors and could serve as markers with potential clinical use...
  28. doi request reprint Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials
    Federica Cuppone
    Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
    Cancer 113:238-46. 2008
    ..A literature-based meta-analysis of randomized clinical trials (RCTs) to 'weigh' how much taxanes add to anthracyclines as primary treatment over standard chemotherapy was conducted...
  29. ncbi request reprint Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree
    Alain Gelibter
    Division of Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy
    Cancer 104:1237-45. 2005
    ..Gemcitabine infusion at the fixed dose rate of 10 mg/m(2) per minute (FDR-gemcitabine) has pharmacokinetic advantages and may result in improved therapeutic efficacy...
  30. ncbi request reprint Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials
    Emilio Bria
    Department of Medical Oncology, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Roma, Italy
    Cancer Treat Rev 32:583-7. 2006
    ..We performed a literature-based meta-analysis of all randomized clinical trials (RCTs) comparing weekly over 3-weekly docetaxel in advanced NSCLC...
  31. ncbi request reprint Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus
    Donatella Del Bufalo
    Laboratory of Experimental Chemotherapy and Division of Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy
    Cancer Res 66:5549-54. 2006
    ..Overall, these results suggest that antiangiogenic effects may substantially contribute to the antitumor activity observed with temsirolimus in breast cancer...
  32. doi request reprint Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function
    Alessandra Felici
    Laboratory of Pharmacokinetics, Regina Elena Cancer Institute, Rome, Italy
    Clin Pharmacokinet 48:131-41. 2009
    ..The primary aim of this study was to evaluate the pharmacokinetics of dFdC and its metabolite difluorodeoxyuridine (dFdU) in patients with normal and impaired hepatic function...
  33. ncbi request reprint New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials
    Paolo Carlini
    Department of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy
    Cancer 104:1335-42. 2005
    ....
  34. ncbi request reprint Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials
    Emilio Bria
    Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
    Breast Cancer Res Treat 109:231-9. 2008
    ..In order to quantify the magnitude of these two risks, and then balance those with the survival outcome, a literature-based meta-analysis was performed...
  35. ncbi request reprint Development and specificities of anti-interferon neutralizing antibodies in patients with chronic hepatitis C treated with pegylated interferon-α
    C Scagnolari
    Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Rome, Italy
    Clin Microbiol Infect 18:1033-9. 2012
    ..This study emphasizes the importance of evaluating NAB development in CHC patients who become resistant to PEG-IFN-α treatment, and suggests management alternatives for patients who develop NAB...
  36. ncbi request reprint The mTOR pathway: a new target in cancer therapy
    L Ciuffreda
    Division of Medical Oncology A, Regina Elena National Cancer Institute, Via Elio Chianesi n 53, 00144 Rome, Italy
    Curr Cancer Drug Targets 10:484-95. 2010
    ..In this review, we discuss mTOR biology and regulation, the mode of action of mTOR inhibitors as anti-cancer agents, and current clinical evidence supporting the use of rapamycin-like mTOR inhibitors in cancer treatment...
  37. ncbi request reprint Changes of gallbladder and gastric dynamics in patients with acute hepatitis A
    P Portincasa
    University Medical School, Bari, Italy, Division of Internal Medicine, Bisceglie, Italy
    Eur J Clin Invest 31:617-22. 2001
    ..Gastric emptying is delayed during the first week of disease and is associated with dyspeptic symptoms...
  38. pmc Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder
    M Milella
    Department of Experimental Medicine and Pathology, University of Rome La Sapienza, Rome, Italy
    Br J Cancer 79:770-9. 1999
    ..These findings may offer support to the development of an IL-2-based gene therapy approach to human bladder cancer...
  39. ncbi request reprint Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients
    Paolo Carlini
    Department of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy
    Cancer Invest 25:102-5. 2007
    ..Few clinical data are published on the sequential use of different classes of aromatase inhibitors...
  40. ncbi request reprint Impact of gefitinib ('Iressa') treatment on the quality of life of patients with advanced non-small-cell lung cancer
    Alain Gelibter
    Division of Medical Oncology A, Regina Elena Cancer Institute, Via Elio Chianesi, 53, 00144, Rome, Italy
    J Cancer Res Clin Oncol 131:783-8. 2005
    ..Patients with advanced non-small-cell lung cancer (NSCLC) have a short life expectancy; therefore, in addition to increasing their survival, improving their quality of life (QoL) is also an important treatment goal...
  41. ncbi request reprint Aromatase inhibitors in post-menopausal metastatic breast carcinoma
    Paolo Carlini
    Regina Elena Cancer Institute, Division of Medical Oncology A, Rome, Italy
    Expert Opin Investig Drugs 16:1023-36. 2007
    ..In the metastatic setting, results are limited and are based on retrospective analyses...
  42. ncbi request reprint Clinically meaningful response to the EGFR tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in non small cell lung cancer
    A Gelibter
    Division of Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy
    J Exp Clin Cancer Res 22:481-5. 2003
    ....
  43. ncbi request reprint PET scanning evaluation of response to imatinib mesylate therapy in gastrointestinal stromal tumor (GIST) patients
    Alain Gelibter
    Regina Elena National Cancer Institute, Rome, Italy
    Anticancer Res 24:3147-51. 2004
    ....
  44. ncbi request reprint Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials
    Emilio Bria
    Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
    Cancer 115:3446-56. 2009
    ..To quantify the magnitude of benefit of the addition of hormone treatment (HT) to exclusive radiotherapy for locally advanced prostate cancer, a literature-based meta-analysis was conducted...
  45. pmc Targeting targeted agents: open issues for clinical trial design
    Emilio Bria
    Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
    J Exp Clin Cancer Res 28:66. 2009
    ..Targeted trial designs can result in easier studies, with less, better selected, and supported by stronger proofs of response evidences, patients, in order to not waste time and resources...
  46. ncbi request reprint Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials
    Federica Cuppone
    Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
    Cancer 112:260-7. 2008
    ..0] was demonstrated...
  47. doi request reprint Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials
    Emilio Bria
    Department of Medical Oncology, Regina Elena National Cancer Institute, Roma, Italy
    Lung Cancer 63:50-7. 2009
    ....
  48. ncbi request reprint Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis
    Bing Z Carter
    Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 448, Houston, TX 77030, USA
    Blood 102:4179-86. 2003
    ..This may partially explain the lack of prognostic impact of XIAP and Survivin and may suggest caspase-independent mechanisms of cell death in AML...
  49. ncbi request reprint The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate
    Simona Gatto
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Haematologica 88:853-63. 2003
    ..We intended to evaluate the effect of PS-341 on proliferation, survival, and cellular events in Bcr/Abl-positive cells sensitive and resistant to IM, and to investigate the effect of PS-341 and IM in conjunction...
  50. doi request reprint Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer
    Giulio Metro
    Oncologist 12:1467-9; author reply 1469-71. 2007
  51. ncbi request reprint Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors
    James A McCubrey
    Brody School of Medicine at East Carolina University, Department of Microbiology and Immunology, 600 Moye Boulevard, Greenville, NC 27858, USA
    Curr Opin Investig Drugs 9:614-30. 2008
    ..The effective targeting of this pathway may result in the suppression of cell growth, and death of malignant cells. This review focuses on targeting the Raf/MEK/ERK pathway with small-molecule inhibitors for the treatment of cancer...
  52. pmc Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
    James A McCubrey
    Department of Microbiology and Immunology, Leo Jenkins Cancer Center, Brody School of Medicine at East Carolina University, Greenville, NC 27858, USA
    Biochim Biophys Acta 1773:1263-84. 2007
    ....
  53. ncbi request reprint Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?
    Paolo Carlini
    J Clin Oncol 24:e60-1. 2006
  54. ncbi request reprint ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia
    Chiara Gregorj
    Division of Hematology, Department of Cellular Biotechnologies and Hematology, University La Sapienza of Rome, Italy
    Blood 109:5473-6. 2007
    ..027). Effective approaches toward MEK inhibition need to be explored in order to evaluate whether this may represent a new therapeutic strategy for adult ALL patients...
  55. ncbi request reprint HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear?
    Gianluigi Ferretti
    J Clin Oncol 22:568-9. 2004
  56. ncbi request reprint Autoantibody signature in human ductal pancreatic adenocarcinoma
    Barbara Tomaino
    Center for Experimental Research and Medical Studies and University of Turin, San Giovanni Battista Hospital, Turin, Italy
    J Proteome Res 6:4025-31. 2007
    ..The results of further studies of these serological-defined antigens could be of diagnostic and therapeutic significance in PDAC...
  57. ncbi request reprint Re: Mastectomy and oophorectomy by menstrual cycle phase in women with operable breast cancer
    Michele Milella
    J Natl Cancer Inst 94:1719-20; author reply 1721-2. 2002
  58. ncbi request reprint Old age: biologic versus chronologic
    Alain J Gelibter
    J Clin Oncol 25:e8. 2007